BZFD vs. TOI, IHRT, TSQ, MDIA, UONE, MYNA, UONEK, FENG, ANGH, and AREN
Should you be buying BuzzFeed stock or one of its competitors? The main competitors of BuzzFeed include Oncology Institute (TOI), iHeartMedia (IHRT), Townsquare Media (TSQ), MediaCo (MDIA), Urban One (UONE), Mynaric (MYNA), Urban One (UONEK), Phoenix New Media (FENG), Anghami (ANGH), and The Arena Group (AREN).
Oncology Institute (NASDAQ:TOI) and BuzzFeed (NASDAQ:BZFD) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, community ranking, institutional ownership, valuation, risk, dividends, profitability, media sentiment and analyst recommendations.
Oncology Institute has a beta of 0.64, meaning that its stock price is 36% less volatile than the S&P 500. Comparatively, BuzzFeed has a beta of 3.36, meaning that its stock price is 236% more volatile than the S&P 500.
36.9% of Oncology Institute shares are owned by institutional investors. Comparatively, 37.6% of BuzzFeed shares are owned by institutional investors. 9.5% of Oncology Institute shares are owned by company insiders. Comparatively, 20.3% of BuzzFeed shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
In the previous week, Oncology Institute had 5 more articles in the media than BuzzFeed. MarketBeat recorded 9 mentions for Oncology Institute and 4 mentions for BuzzFeed. Oncology Institute's average media sentiment score of 0.34 beat BuzzFeed's score of -0.17 indicating that BuzzFeed is being referred to more favorably in the news media.
Oncology Institute currently has a consensus target price of $2.50, indicating a potential upside of 375.47%. Given BuzzFeed's higher probable upside, analysts plainly believe Oncology Institute is more favorable than BuzzFeed.
Oncology Institute has a net margin of -20.28% compared to Oncology Institute's net margin of -32.51%. Oncology Institute's return on equity of -58.08% beat BuzzFeed's return on equity.
Oncology Institute has higher revenue and earnings than BuzzFeed. BuzzFeed is trading at a lower price-to-earnings ratio than Oncology Institute, indicating that it is currently the more affordable of the two stocks.
Oncology Institute received 2 more outperform votes than BuzzFeed when rated by MarketBeat users. Likewise, 66.67% of users gave Oncology Institute an outperform vote while only 11.11% of users gave BuzzFeed an outperform vote.
Summary
Oncology Institute beats BuzzFeed on 10 of the 17 factors compared between the two stocks.
Get BuzzFeed News Delivered to You Automatically
Sign up to receive the latest news and ratings for BZFD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BZFD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BuzzFeed Competitors List
Related Companies and Tools
